期刊文献+

卡巴他赛注射液与输液装置相容性试验中元素杂质迁移研究

Study on Elemental Impurities Migration in Compatibility Test of Cabazitaxel Injection and Infusion Device
在线阅读 下载PDF
导出
摘要 建立电感耦合等离子体发射光谱法(ICP-OES)测定卡巴他赛注射液与输液装置相容性试验中镁和铝的含量。采用微波消解法处理样品,分别以280.270和396.153 nm作为ICP-OES测定镁和铝含量的分析谱线。结果显示,镁和铝的质量浓度均在0.02~1μg·mL^(-1)范围内与相应的响应强度呈良好的线性关系,R分别为0.99999和0.99995,检测下限分别为0.00009和0.004μg·mL^(-1),平均回收率(n=9)均在86.3%~101.8%。3批0.9%氯化钠注射液-卡巴他赛注射液铝元素含量均小于定量限,镁元素含量均小于0.007μg/mL;3批5%葡萄糖注射液-卡巴他赛注射液铝元素均未检出(检出限为0.004μg/mL),镁元素含量均小于0.001μg/mL。该方法灵敏度高、准确好,适用于甲卡巴他赛注射液与输液装置相容性试验中镁和铝的含量检测。 To establish a method for simultaneous determination of magnesium and aluminium in cabazitaxel injection by inductively coupled plasma emission spectrometry(ICP-OES)method.The sample was digested by microwave and determined by ICP-OES using analytical lines of elements of 280.270 nm for magnesium and 396.153 nm for aluminium.The concentration of magnesium and aluminium in the range of 0.02~1μg·mL^(-1)showed a good linear relationship with the R of 0.99999 and 0.99995,respectively,and the detection limits were 0.00009 and 0.004μg·mL^(-1),respectively,and average recoveries were 86.3%~101.8%.In the three batches of samples with 0.9%sodium chloride injection,the contents of aluminium were all less than LOQ,and the contents of magnesium were all less than 0.007μg·mL^(-1).In the three batches of samples with 5%glucose injection,the contents of aluminium were all less than LOD,and the contents of magnesium were all less than 0.001μg·mL^(-1).The method is highly sensitive accurate and reliable,and can be used for the determination of magnesium and aluminium content in compatibility test of cabazitaxel injection and infusion device.
作者 陈江 刘妮妮 张青 张海梅 黄青玲 强文舟 耿少敏 CHEN Jiang;LIU Nini;ZHANG Qing;ZHANG Haimei;HUANG Qingling;QIANG Wenzhou;GENG Shaomin(Department of Pharmacy,Shaanxi Provincial Armed Police Corps Hospitsl,Xi′an 710054,China;Xi′an Xintong Pharmaceutical Research Co.,Ltd.,Xi′an 710077,China)
出处 《山东化工》 2025年第15期136-139,143,共5页 Shandong Chemical Industry
关键词 卡巴他赛注射液 输液装置 电感耦合等离子体发射光谱 cabazitaxel injection Mg Al infusion device ICP-OES
  • 相关文献

参考文献8

二级参考文献74

  • 1Bouchet BP,Gaimarini CM.Cabazitaxel,a new taxane with favorable properties[J].Drugs Today(Barc),2010,46(10):735-742.
  • 2Yoo GH,Kafri Z,Ensley JF,et al.XRP6258-indueed gene expression patterns in head and neck cancer carcinoma[J].Laryngoscope, 2010,120(6):1114-1119.
  • 3Mita AC,Denis LJ,Rowinsky EK,et al.Phase I and phannacoki- ??netic study of XRP6258(P(?)R 116258A),a novel taxane,administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors[J].Clin Cancer Res,2009,15(2):723-730.
  • 4Oudard S.TROPIC;PhaseⅢtrial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer[J].Future Oncol, 2010,7(4):497-506.
  • 5Jevtana[EB/OL].http://www.rxlist.com/jevtana-drug,html, 2010-07-14/2011-08-21.
  • 6De Bono JS,Oudard S,Ozguroglu M.et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial [J].Lancet,2010,376(9747):1147-1154.
  • 7Figg WD.Cabazitaxel:filling one of the gaps in the treatment of prostate cancer[J].Cancer Biol Ther,2011,10(12):1233-1234.
  • 8Jemal A, Siegel R, Xu J, et al. Cancer statistics [J]. CACancer J Clin, 2010, 60 (5): 277-300.
  • 9D'Amico AV, Cote K,Loffredo M, et al. Determinants ofprostate cancer-specific survival after radiation therapy forpatients with clinically localized prostate cancer [J]. J ClinOncol, 2002, 20(23): 4567-4573.
  • 10Tannock IF, Osoba D, Stockier MR, et al. Chemotherapywith mitoxantrone plus prednisone or prednisone alone forsymptomatic hormone-resistant prostate cancer: a Canadianrandomized trial with palliative end points [J]. J Clin Oncol,1996,14(6): 1756-1764.

共引文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部